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Epidemiology of Bloodstream Infections in a
Multicenter Retrospective Cohort of Liver
Transplant Recipients
Carlos A.Q. Santos, MD,1 Richard S. Hotchkiss, MD,2 William C. Chapman, MD,3 Margaret A. Olsen, PhD, MPH1,4
Background.Although some studies have examined the epidemiology of bloodstream infections after liver transplantation, they
were based in single centers and did not identify bloodstream infections treated in other hospitals.Methods.We retrospectively
examined a cohort of 7912 adult liver transplant recipients from 24 transplant centers using 2004 to 2012 International Classifica-
tion of Diseases, Ninth Revision, Clinical Modification billing data from 3 State Inpatient Databases, and identified bloodstream
infections, inpatient death, and cumulative 1-year hospital costs. Multilevel Cox regression analyses were used to determine
factors associated with bloodstream infections and death. Results. Bloodstream infections were identified in 29% (n = 2326)
of liver transplant recipients, with a range of 19% to 40% across transplant centers. Only 63% of bloodstream infections occurring
more than 100 days posttransplant were identified at the original transplant center. Bloodstream infections were associated
with posttransplant laparotomy (adjusted hazard ratio [aHR], 1.52), prior liver transplant (aHR, 1.42), increasing age (aHR, 1.07/
decade), and some comorbidities. Death was associated with bloodstream infections with and without septic shock (aHR,
10.96 and 3.71, respectively), transplant failure or rejection (aHR, 1.41), posttransplant laparotomy (aHR, 1.40), prior solid-
organ transplant (aHR, 1.48), increasing age (aHR, 1.15/decade), and hepatitis C cirrhosis (aHR, 1.20). The risk of bloodstream
infections and death varied across transplant centers. Median 1-year cumulative hospital costs were higher for patients who de-
veloped bloodstream infections within 1 year of transplant compared with patients who were bloodstream infection-free (US
$229 806 vs US $111 313; P < 0.001).Conclusions. Bloodstream infections are common and costly complications after liver
transplantation that are associated with a markedly increased risk of death. The incidence and risk of developing bloodstream in-
fections may vary across transplant centers.
(Transplantation Direct 2016;2: e67; doi: 10.1097/TXD.0000000000000573. Published online 22 February 2016.)
L iver transplantation has a 1- and 5-year graft survivalrate of 90% and 70%, respectively, that has been en-
abled by refinements in surgical technique and advances in
immunosuppressive and preventive anti-infective therapy.1
However, bloodstream infections can limit posttransplant
patient survival by culminating in multiorgan failure, septic
shock, and death.2-5
Recently published single-center studies show that blood-
stream infections occur in 17%to 29%of liver transplant recip-
ients6-9 and are associated with an increased risk of death.8,9
Commonly isolated microorganisms were Staphylococcus
aureus, Enterococcus species, Escherichia coli, Klebsiella
pneumoniae, and Pseudomonas aeruginosa, and frequentlyReceived 13 August 2015.
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originated from abdominal, pulmonary, and urinary tract
sources.7,8 Patients infected with carbapenem-resistantK. pneu-
moniae had a particularly high mortality rate.9 Although these
studies increase our understanding of the incidence, microbiol-
ogy, and outcomes of bloodstream infections after liver trans-
plantation, they are based in single transplant centers that may
have missed bloodstream infections treated in other hospitals.
To determine the epidemiology of bloodstream infections
after liver transplantation, we assembled a large and more
representative cohort of liver transplant recipients from mul-
tiple centers using theHealthcare Cost andUtilization Project
State Inpatient Databases (SID). The SID comprise of demo-
graphic and billing data that capture inpatient diagnoses and
procedures through International Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) coding10
and has been used in the field of liver transplantation to study
perioperative complications of live liver donors,11 delayed-
onset cytomegalovirus disease,12 and relationships between
hospital/surgeon volume and inpatient mortality.13 The
ICD-9-CM codes used to identify bloodstream infections in
this study have been validated, with a positive predictive
value of 89% and a negative predictive value of 80%.14
Our approach allowed us to follow a large number of pa-
tients for a long period, identify bloodstream infections
regardless of whether patients were readmitted to the trans-
plant hospital or a different hospital, and determine hospital
costs. We hypothesized that a significant proportion of blood-
stream infections are treated in hospitals other than the origi-
nal transplant center, and that bloodstream infections are
associated with increased hospital costs and death.
METHODS
Data Sources
We used the SID from California (2003 to 2011), Florida
(2005 to 2013), and New York (2005 to 2012) because of
the availability of encrypted patient-level identifiers that link
admissions across hospitals over time within a state. The
ICD-9-CM diagnosis and procedure codes used in this study
are listed inTable S1 (SDC, http://links.lww.com/TXD/A21).
Study Design and Patient Population
We performed a retrospective cohort study of persons
18 years or older who underwent liver transplantation in
nonpediatric hospitals (identified by the American Hospital
Association Annual Hospital Survey) from 2004 to 2010 in
the California SID, 2006 to 2012 in the Florida SID, and
2006 to 2011 in the New York SID (n = 9096). We chose the
cohort inception years to accrue 1 year of preexisting data to
determine comorbidities and at least 1 year of follow-up data.
We excluded persons who lived outside of the state where the
transplant was performed because we would not be able to
track bloodstream infections during readmission in those in-
dividuals (n = 1088), and persons who died 2 days or less
posttransplant because they would not have had the oppor-
tunity to develop bloodstream infections (n = 96). The final
study population consisted of 7912 liver transplant recipients
(Figure 1). This studywas considered exempt by theWashington
University Institutional Review Board.
Patient Characteristics
Demographic data were determined at the time of liver
transplantation. Possible reasons for liver transplant, prior
solid-organ transplant, and Elixhauser comorbidities were
identified within 1 year before liver transplant and during
the transplant hospitalization.15
Transplant Center Characteristics
Wedetermined themean annual number of liver transplants
at each transplant center and classified hospitals as either small
(<25 transplants/yr), medium (26 to 75 transplants/yr), or
large (>75 transplants/yr) transplant centers by volume. We
used American Hospital Association Annual Survey data to
determine the number of adult acute-care medical/surgical
beds at each transplant center and identify its teaching status
(presence or absence of residents-in-training).
Bloodstream Infections
Bloodstream infections that occurred posttransplant were
identified using ICD-9-CM codes in Table S1 (SDC, http://
links.lww.com/TXD/A21). Bloodstream infections that oc-
curred during the transplant hospitalization were defined as
occurring after transplantation if it was not the primary diag-
nosis coded for the hospitalization and if 15 days or less
elapsed from day of admission to day of transplant, to mini-
mize the probability of capturing bloodstream infections
occurring before transplant. The time of bloodstream infec-
tion was defined as the midpoint between the day of trans-
plant and the day of discharge for bloodstream infections
that occurred during the transplant hospitalization, and the
day of admission for bloodstream infections that were identi-
fied on readmission. Bloodstream infections were empirically
categorized as either early-onset (occurring < 100 days post-
transplant) or delayed-onset (occurring > 100 days posttrans-
plant) based on the median onset of bloodstream infection,
and as perioperative (occurring < 30 days post-transplant)
or nonperioperative (occurring > 30 days posttransplant).
Possible sources of infection were defined as concurrent cod-
ing for intra-abdominal infections, pneumonia, empyema,
and other chest infections, urinary tract infection, endocardi-
tis, and other blood vessel infections, septic arthritis and oste-
omyelitis, and central nervous system infections. Possible
complications of bloodstream infection were defined as
concurrent coding for acute organ dysfunction and septic
shock.14 The hospitals where bloodstream infections were
identified indicated whether patients were treated at the orig-
inal transplant center or another hospital.
Death and Other Conditions
Time of inpatient death was determined using the discharge
status variable. Other conditions identified on follow-up were
FIGURE 1. Cohort inception of 7912 liver transplant recipients.
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newly coded transplant failure or rejection, posttransplant
laparotomy, hemodialysis, and repeat solid-organ transplant
during readmission (Table S1, SDC, http://links.lww.com/
TXD/A21).
Hospital Costs
Hospital costs for the transplant hospitalization and any
subsequent readmission 1 year or less after transplantation
were summed to arrive at cumulative 1-year hospital costs
for the study population, after converting hospital charges
to costs using the Healthcare Cost and Utilization Project
cost-to-charge ratio file,16 and adjusting for inflation to
2013 US dollars with the medical care component of the
Consumer Price Index.17 Hospital costs were then compared
between persons who developed bloodstream infection
1 year or less posttransplant and persons who were blood-
stream infection-free.
Statistical Analysis
Descriptive statistics were used to describe the demo-
graphic and clinical characteristics of the study population.
Kruskall-Wallis testing was performed to determine if cumu-
lative 1-year hospital costs were statistically significantly
higher for persons who developed bloodstream infection
1 year or less posttransplant compared with persons who
were bloodstream infection-free. Spearman rank-order test-
ing was performed to determine if incidence of bloodstream
infections and death across transplant centers was correlated.
Multilevel Cox regression analyses with random intercepts
by transplant center were performed to identify patient-
level and transplant center-level factors associated with
bloodstream infection and death while accounting for shared
frailties in developing bloodstream infection and death in
persons from the same transplant center. Clinically meaning-
ful patient-level and transplant center-level variables that
could be potential risk factors for bloodstream infection
and death were specified and evaluated for proportionality
and time dependency using visual inspection of log-log sur-
vival curves and examination of Schoenfeld residuals.18 A se-
ries of Cox regression models starting with a hierarchically
well-formulated initial model followed by iterative backward
elimination resulted in a penultimate model that was assessed
for confounding and precision to arrive at the final model.19
Statistical significance was set at a P value of 0.05 or less. All




The study population consisted of 7912 adult liver trans-
plant recipients (Table 1). The median age was 56 years;
33% were women, 56% were white, 22% were Hispanic,
74% lived in large metropolitan areas, and 52% had private
insurance. Commonly identified possible reasons for liver
transplant were hepatitis C cirrhosis (44%), hepatocellular
carcinoma (36%), and alcoholic cirrhosis (34%). Two per-
cent of patients had prior solid-organ transplantation. Com-
monly identified comorbidities were hypertension (49%),
diabetes mellitus (34%), and renal failure (19%). The me-
dian duration of follow-up was 4 years (interquartile range,
2.1-5.9 years).
TABLE 1.
Demographic and clinical characteristics of liver transplant re-
cipients in the study cohort at the time of organ transplantation
Variables All recipients, n = 7912
Age, y
Mean ± SD 54.38 ± 10.01
Median (interquartile range) 56 (50-61)





Asian or Pacific Islander 8.06
Other or missing 6.67




Not metropolitan or micropolitan, or missing 1.40
Median income of patient ZIP code (%)
First quartile (poorest) 20.70
Second quartile 23.10
Third quartile 23.90
Fourth quartile (wealthiest) 23.95
Missing 8.34
Expected primary insurance payer (%)
Medicare 26.93
Private insurance 51.50
Medicaid, self-pay, no charge, other, or missing 21.56
Possible reasons for liver transplant, %
Hepatitis C cirrhosis 43.69
Hepatocellular carcinoma 36.29
Alcoholic cirrhosis 34.11
Cirrhosis, no viral etiology identified 16.92
Hepatitis B cirrhosis 9.37
Nonalcoholic steatohepatitis 8.34
Biliary cirrhosis 4.97












Pulmonary circulation disease 6.74
Congestive heart failure 6.08
Valvular disease 5.46
Duration of follow-up, years
Mean 4.0
Median (interquartile range) 4.0 (2.1-5.9)
a Large metropolitan—at least 1 million residents; small metropolitan—less than 1 million residents;
micropolitan—adjacent to large or small metropolitan area.
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Transplant Center Characteristics
There were 24 hospitals that performed liver transplants
for the study population (Table 2). The mean number of liver
transplants performed by each hospital per year was 49, and
the mean number of acute-care beds was 404. Six hospitals
were small (<25 transplants/year), 12 were medium (26-75
transplants/year), and 6 were large (>75 transplants/year)
transplant centers. Ninety-two percent of transplant centers
were teaching hospitals.
Bloodstream Infections
Bloodstream infections were identified in 29% of liver
transplant recipients, with a range of 19% to 40% across
transplant centers (Figure 2A). Fifty-two percent of blood-
stream infections occurred 100 days or less posttransplant
(early-onset), and 48% occurred more than 100 days
posttransplant (delayed-onset) (Table 3). Thirty-four percent
of bloodstream infections occurred 30 days or less post-
transplant (perioperative), and 66% occurred more than
30 days posttransplant (nonperioperative). Coding for Gram-
negative or anaerobic bacteria, Gram-positive bacteria, mul-
tiple microorganisms, and fungus accounted for 23%, 22%,
8%, and 3% bloodstream infections, respectively, whereas
unspecified microorganisms (eg, “bacteremia”) were coded
in 44%. Common possible sources of infection were intra-
abdominal infections (55%), pneumonia, empyema, and
other chest infections (37%), urinary tract infection (22%),
endocarditis, and other blood vessel infections (7%). Signifi-
cantly more early-onset bloodstream infections had concur-
rent coding for intra-abdominal and pulmonary infections
than delayed-onset bloodstream infections (70% vs 40%
and 42% vs 31%, respectively). Acute organ dysfunction,
multiorgan failure, and septic shock were identified in
78%, 54%, and 19% of bloodstream infection hospital-
izations, respectively. Renal (64%), cardiovascular (27%),
respiratory (27%), and hematologic (26%) dysfunction com-
monly occurred. Eighty-one percent of patients with blood-
stream infection were diagnosed and treated in the original
transplant center. Although 97% of early-onset bloodstream
infections were identified at the original transplant center,
only 63% of delayed-onset bloodstream infections were
identified at the original transplant center. Thirty-four per-
cent of patients with bloodstream infections died, with a me-
dian time to death of 47 days from the bloodstream infection
hospitalization (interquartile range, 15-206 days).
Risk factors for bloodstream infections are in Table 4. In
multivariate analysis, posttransplant laparotomy (hazard ra-
tio [HR], 1.52), increasing age at time of transplantation per
decade (HR, 1.07), female sex (HR, 1.13), prior liver trans-
plant (HR, 1.42), diabetes mellitus (HR, 1.12), renal failure
(HR, 1.27), chronic pulmonary disease (HR, 1.22), and
congestive heart failure (HR, 1.23) were associated with an
increased risk of bloodstream infections. Hepatocellular car-
cinoma (HR, 0.80) was associated with a decreased risk of
bloodstream infections. Of 24 transplant centers, 4 were sig-
nificantly more likely than average to have populations that
developed bloodstream infections and 3 were significantly
less likely than average to have populations that developed
bloodstream infections (Figure 3A).
Median 1-year cumulative hospital costs were higher
for patients who developed bloodstream infections within
1 year of transplant comparedwith patients whowere blood-
stream infection-free (US $229 806 vs $111 313; P < 0.001)
(Figure 4).
Inpatient Death
Inpatient death was identified in 15% of patients, with a
range of 7% to 25% across transplant centers (Figure 2B).
The incidence of bloodstream infections and death across
transplant centers were strongly correlated (Spearman
TABLE 2.
Hospital characteristics of liver transplant centers
Variables All hospitals, n = 24
No. liver transplants performed per year
Mean ± SD 48.96 ± 34.15
Median (range) 43 (2-139)
Transplant center size by mean number of liver transplants performed per year (%)
Small (<25) 6 (25.00)
Medium (26-75) 12 (50.00)
Large (>75) 6 (25.00)
Number of adult acute-care medical/surgical beds
Mean ± SD 403.62 ± 262.20
Median (range) 338 (80-1081)
Transplant center size by bed number
Small (<250) 7 (29.17)
Medium (251 to 500) 10 (41.67)
Large (>500) 7 (29.17)
Teaching hospital (%) 22 (91.67)
FIGURE 2. Incidence of bloodstream infections (A) and inpatient
death (B) stratified according to transplant center. Bubbles signify rel-
ative sizes of transplant centers by mean number of liver transplants
per year. Dashed line indicates themean incidence for the population.
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correlation coefficient, 0.66; P < 0.001). Thirty-two per-
cent of deaths occurred 100 days or less posttransplant, and
68% occurred more than 100 days posttransplant (Table 3).
Common conditions during the death hospitalization were
bloodstream infections (64%), transplant failure or rejection
(53%), and hemodialysis (42%).
Risk factors for death are in Table 5. In multivariate anal-
ysis, bloodstream infections without septic shock (HR, 3.71),
bloodstream infections with septic shock (HR, 10.96), trans-
plant failure or rejection (HR, 1.41), posttransplant laparot-
omy (HR, 1.40), increasing age at time of transplantation per
decade (HR, 1.15), hepatitis C cirrhosis (HR, 1.20), and prior
solid-organ transplant (HR, 1.48) were associated with an in-
creased risk of death. Of 24 transplant centers, 4 were signifi-
cantly more likely than average to have populations that died
and 2 were significantly less likely than average to have popu-
lations that died (Figure 3B). Bloodstream infections with or
without septic shock (HR, 4.8), early-onset bloodstream
infections (HR, 5.3), and delayed-onset bloodstream infec-
tions (HR, 4.3) were associated with increased risk of death
after adjusting for the same covariates.
DISCUSSION
We found that bloodstream infections were common and
costly complications after liver transplantation that were as-
sociated with a nearly 5-fold increased risk of death. These
results identify bloodstream infections as significant impedi-
ments to successful liver transplantation across multiple
transplant centers and highlight the need for more clinical
and translational research into how bloodstream infections
in these vulnerable hosts can be better prevented and treated.
Interestingly, almost half of first episodes of bloodstream in-
fection were identified more than 100 days posttransplant, of
which nearly 40% were treated at a hospital other than the
original transplant center. This finding underscores the ability
TABLE 3.
No. patients with bloodstream infections and inpatient death coded during hospitalization in a cohort of 7912 liver transplant
recipients
All Early (<100 d posttransplant) Delayed (>100 d posttransplant)
Bloodstream infections
No. patients (%) 2326 (29.40) 1212 (52.11) 1114 (47.89)
Microorganism
Gram-negative or anaerobic bacteria 524 (22.53) 251 (20.71) 273 (24.51)
Gram-positive bacteria 518 (22.27) 281 (23.18) 237 (21.27)
Multiple organisms 192 (8.25) 131 (10.81) 61 (5.48)
Fungus 62 (2.67) 38 (3.14) 24 (2.15)
No specific microorganism 1030 (44.28) 511 (42.16) 519 (46.59)
Possible source of infection
Intra-abdominal infections 1290 (55.46) 847 (69.88) 443 (39.77)
Pneumonia, empyema, other chest infections 858 (36.89) 510 (42.08) 348 (31.24)
Urinary tract infection 506 (21.75) 250 (20.63) 256 (22.98)
Endocarditis, other blood vessel infections 165 (7.09) 73 (6.02) 92 (8.26)
Septic arthritis, osteomyelitis 20 (0.86) * *
Meningitis, brain abscess, spinal abscess 11 (0.47) * *
No identifiable possible source of infection 436 (18.74) 160 (13.20) 276 (24.78)
Acute organ dysfunction
Renal 1479 (63.59) 786 (64.85) 693 (62.21)
Cardiovascular 632 (27.17) 352 (29.04) 280 (25.13)
Respiratory 622 (26.74) 369 (30.45) 253 (22.71)
Hematologic 614 (26.40) 384 (31.68) 230 (20.65)
Metabolic 427 (18.36) 217 (17.90) 210 (18.85)
Hepatic 416 (17.88) 297 (24.50) 119 (10.68)
Neurologic 262 (11.26) 138 (11.39) 124 (11.13)
Multiorgan failure (>2 acute organ dysfunction) 1256 (54.00) 730 (60.23) 526 (47.22)
Septic shock 453 (19.48) 252 (20.79) 201 (18.04)
Admitted to the original liver transplant center 1877 (80.70) 1174 (96.86) 703 (63.11)
Died 802 (34.48) 412 (33.99) 390 (35.01)
Median time to death in days after admission with bloodstream
infection (interquartile range)
47 (15-206) 44 (16-227) 51 (15-176)
Inpatient death
No. patients (%) 1180 (14.91) 380 (32.20) 800 (67.80)
Bloodstream infection 756 (64.07) 264 (69.47) 492 (61.50)
Transplant failure or rejection 628 (53.22) 174 (45.79) 454 (56.75)
Dialysis 497 (42.12) 204 (53.68) 293 (36.63)
a AHRQ-HCUP prohibits reporting cell sizes <11 in number.
AHRQ-HCUP, Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project
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of our analysis to identify bloodstream infections over a long
period, and regardless of whether patients were readmitted
to the transplant center or another hospital. Delayed-onset
bloodstream infections were less commonly concurrently
coded with intra-abdominal infections than were early-onset
infections, likely reflecting a shift away from the surgical site
as an obvious source of infection as time elapses after trans-
plant.7,8 In contrast, urinary tract, endovascular, bone and
joint, and central nervous system infections were more com-
monly concurrently coded with delayed-onset bloodstream
infections than early-onset bloodstream infections. Acute
organ dysfunction, multiorgan failure, and septic shock oc-
curred commonly in hospitalizations wherein bloodstream
infections were identified, and possibly reflect significant mor-
bidity caused by bloodstream infections.7,20,21
Posttransplant laparotomy and prior liver transplant were
the strongest risk factors for bloodstream infections in our
analysis. Return to surgery and prior liver transplant have
previously been shown to be associated with bloodstream in-
fections in single-center studies.8,20,22 Return to surgery is
typically performed for technical complications that arise
posttransplant, and include biliary leak or stricture, portal
vein or hepatic artery thrombosis, hemorrhage and infarc-
tion.23,24 Disrupted anatomy coupled with critical illness,
complex surgery, and prolonged hospitalization may pre-
dispose patients to develop intra-abdominal, pulmonary,
urinary tract, and vascular catheter infections that culminate
in bloodstream infections. Repeat liver transplantation has
higher rates of allograft failure compared with primary liver
transplantation,25,26 which can result in an increased risk of
bloodstream infections. Other risk factors were increasing
age, diabetes mellitus, renal failure, chronic pulmonary dis-
ease, and congestive heart failure, which indicate that comor-
bidities can contribute to increasing the risk of bloodstream
infections among liver transplant recipients. Hepatocellular
carcinoma was associated with a decreased risk of blood-
stream infections, likely because patients who underwent
transplantation for early-stage hepatocellular carcinoma as de-
fined by the Milan criteria27-29 had lower model for end-stage
liver disease (MELD) scores than patients who underwent
transplantation for end-stage liver disease.30,31 Single-center
studies indicate that higher MELD scores are associated with
increased bloodstream infection risk.8,20
We found variability in the shared susceptibilities of liver
transplant recipients clustered within transplant centers in de-
veloping bloodstream infections, after accounting for patient-
level factors that included posttransplant laparotomy, prior
liver transplant, age, sex, and several comorbidities. Themost
likely reason for variability is residual confounding given our
inability to capture all patient-level factors that can be associ-
ated with bloodstream infections. Some transplant centers
operate on sicker and more complicated patients than others,
TABLE 4.
Cox proportional hazard model of risk factors for bloodstream infections
Univariate analysis Multivariate analysis
Risk factor HR (95% CI) P HR (95% CI) P
Patient-level variables
Previous exploratory laparotomy 1.59 (1.43-1.77) <0.001 1.52 (1.36-1.70) <0.001
Increasing age at time of transplantation per decade 1.04 (1.00-1.09) 0.053 1.07 (1.02-1.11) 0.004
Female sex 1.20 (1.10-1.30) <0.001 1.13 (1.04-1.24) 0.004
Possible reasons for liver transplant
Hepatitis C cirrhosis 1.00 (0.92-1.08) 1.000
Hepatocellular carcinoma 0.76 (0.70-0.83) <0.001 0.80 (0.73-0.88) <0.001
Alcoholic cirrhosis 1.05 (0.97-1.14) 0.249
Cirrhosis, no viral etiology identified 1.10 (0.99-1.22) 0.089
Hepatitis B cirrhosis 0.84 (0.73-0.98) 0.022
Non-alcoholic steatohepatitis 1.15 (1.00-1.32) 0.048
Biliary cirrhosis 1.02 (0.85-1.23) 0.797
Prior liver transplant 1.67 (1.31-2.13) <0.001 1.42 (1.10-1.82) 0.006
Other comorbidities
Diabetes mellitus 1.14 (1.04-1.24) 0.003 1.12 (1.02-1.22) 0.015
Renal failure 1.44 (1.31-1.59) <0.001 1.27 (1.15-1.41) <0.001
Chronic pulmonary disease 1.30 (1.16-1.46) <0.001 1.22 (1.08-1.36) 0.001
Obese 1.18 (1.04-1.34) 0.010
Congestive heart failure 1.47 (1.27-1.71) <0.001 1.23 (1.06-1.43) 0.008
Transplant center-level variables
Transplant center size by volume
Small (<25 transplants/y) 1.00
Medium (26 to 75 transplants/y) 1.10 (0.92-1.32) 0.275
Large (>75 transplants/y) 1.00 (0.84-1.19) 0.988
Transplant center size by bed number
Small (<250) 1.00
Medium (251-500) 0.87 (0.79-0.96) 0.006
Large (>500) 0.90 (0.82-1.00) 0.047
Teaching hospital 1.07 (0.83-1.38) 0.587
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which can result in more morbid cohorts who are at greater
risk of bloodstream infections and death than average. Other
possible reasons for variability include shared antibiotic re-
sistance patterns for bacteria among patients transplanted
in the same transplant center,9,20-22,32-34 shared infection
control policies,8,35 and shared surgical teams.23,24 Patients
transplanted in hospitals with high rates of multidrug-
resistant bacteria, such as methicillin-resistant S. aureus, ex-
tended spectrum β lactamase-producing P. aeruginosa and
carbapenem-resistant K. pneumoniae may be at increased
risk of developing bloodstream infections given the reduced
efficacy of first-line antibiotics in treating sources of infec-
tion.9,21 Aggressive infection control policies that have been
shown to reduce the transmission of methicillin-resistant S.
aureus among liver transplant recipients (active surveillance,
contact isolation and decolonization)may bemore effectively
implemented in some transplant centers than others.8,35 Sur-
gical teams in different transplant centers may have varying
levels of technical proficiency, which can lead to different bil-
iary and vascular complication rates23,24 and different risks
of bloodstream infection. Variability in bloodstream infec-
tion risk across transplant centers should be confirmed with
more granular clinical data.
We found that bloodstream infections, multiorgan failure,
and septic shockwere strongly associatedwith death, support-
ing recently published single-center studies.8,9 Some blood-
stream infections can initiate a rapidly vicious circle of
cytokine-driven hyperinflammation, septic shock, and death
within a few days of onset,9,36 whereas others can result in
protracted hospitalization, persistent organ dysfunction, im-
mune exhaustion, and frailty followed by death after several
weeks or months.37 Alternatively, bloodstream infections
may be markers for more direct determinants of death, such
as posttransplant technical complications or acute allograft re-
jection. Although we adjusted for posttransplant laparotomy
and transplant failure or rejection in our Cox regression
models, residual confoundingmay have been present. The pre-
cise role of bloodstream infections in the causal pathway to
death cannot be determined in this retrospective population-
level epidemiologic study.
The strengths of our study are the large size of the study
population, long duration of follow-up, and identification
of bloodstream infections regardless of admission to the
transplant center or another hospital. It however has some
limitations. Comorbidities and clinical events were identified
using ICD-9-CM codes which are not perfectly accurate.38
However, the ICD-9-CM codes used to identify bloodstream
infections in this study have been validated and found to have
reasonable accuracy.14 Moreover, misclassification stem-
ming from occasionally inaccurate ICD-9-CM coding will re-
sult in more conservative estimates of associations between
bloodstream infections and death, or bloodstream infections
and potential risk factors, thereby maintaining the validity
of our results. The data source used in this study contains
only demographic and inpatient hospital ICD-9-CM billing
data occurring within a state and does not havemicrobiology
information, laboratory test results, MELD scores, medica-
tions prescribed, or information regarding the presence of
FIGURE 3. Transplant center-level effects for bloodstream infection
(A) and death (B). Blue circles represent point estimates, and red bars
indicate 95% confidence intervals. Dashed line indicates the average
risk for the population.
FIGURE 4. Natural log of cumulative 1-year hospital costs stratified
according absence (A) or presence (B) of bloodstream infection
within 1 year posttransplant.
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central venous catheters. We therefore could not precisely
identify causative microorganisms, antibiotic susceptibilities,
antimicrobials administered, or whether bloodstream infec-
tions were catheter-related. Although classes of microorgan-
isms were identified in the majority of cases, a significant
proportion of microorganisms were unspecified (eg, “bacter-
emia”). However, Cox regression analyses showed that
unspecified microorganisms were similarly associated with
death as specific microorganisms, indicating comparably
morbid conditions. Despite its limitations, our study pro-
vides population-level information regarding the epidemiol-
ogy of bloodstream infections after liver transplantation
in the current era, identifies variability in the incidence and
risk of developing bloodstream infections and death across
transplant centers after accounting for many patient-level
factors, and highlights the need for further research regard-
ing better prevention and management strategies for blood-
stream infections across transplant centers nationally.
In summary, we showed that bloodstream infections after
liver transplantation were common and costly complications
that were associated with a markedly increased risk of death.
The incidence and risk of developing bloodstream infections
may vary across transplant centers. Better prevention and
management strategies should be subjects of future research.
TABLE 5.
Cox proportional hazard model of risk factors for inpatient death
Univariate analysis Multivariate analysis
Risk factor HR (95% CI) P HR (95% CI) P
Patient-level variables
Bloodstream infections 5.73 (5.07-6.48) <0.001
Microorganism
Gram-negative or anaerobic bacteria 5.34 (4.46-6.40) <0.001
Gram-positive bacteria 4.73 (3.93-5.70) <0.001
Multiple organisms 7.58 (5.97-9.62) <0.001
Fungus 5.40 (3.44-8.46) <0.001
No specific microorganism 6.17 (5.35-7.12) <0.001
Without multiorgan failure 2.96 (2.50-3.50) <0.001
With multiorgan failure 8.70 (7.64-9.90) <0.001
Early-onset (<100 days posttransplant) 6.19 (5.38-7.12) <0.001
Delayed-onset (>100 days posttransplant) 5.32 (4.62 – 6.12) <0.001
Without septic shock 4.44 (3.89-5.06) <0.001 3.71 (3.23-4.26) <0.001
With septic shock 12.98 (11.11-15.16) <0.001 10.96 (9.31-12.90) <0.001
Transplant failure or rejection 2.31 (2.03-2.62) <0.001 1.41 (1.23-1.61) <0.001
Posttransplant laparotomy 2.20 (1.93-2.51) <0.001 1.40 (1.22-1.61) <0.001
Increasing age at time of transplantation per decade 1.12 (1.05-1.19) <0.001 1.15 (1.06-1.35) <0.001
Female sex 1.19 (1.05-1.34) 0.005
Possible reasons for liver transplant
Hepatitis C cirrhosis 1.26 (1.12-1.41) <0.001 1.20 (1.06-1.35) 0.003
Hepatocellular carcinoma 1.00 (0.89-1.13) 1.000
Alcoholic cirrhosis 1.02 (0.91-1.16) 0.684
Cirrhosis, no viral etiology identified 0.90 (0.77-1.06) 0.194
Hepatitis B cirrhosis 0.94 (0.77-1.15) 0.570
Nonalcoholic steatohepatitis 0.97 (0.79-1.20) 0.808
Biliary cirrhosis 0.76 (0.56-1.02) 0.065
Prior solid-organ transplant 1.93 (1.44-2.59) <0.001 1.48 (1.10-1.99) 0.011
Other comorbidities
Diabetes mellitus 1.13 (1.00-1.27) 0.044
Renal failure 1.29 (1.12-1.48) <0.001
Chronic pulmonary disease 1.24 (1.06-1.45) 0.001
Obese 0.98 (0.81-1.18) 0.815
Congestive heart failure 1.55 (1.26-1.89) <0.001
Transplant center-level variables
Transplant center size by volume
Small (<25 transplants/y) 1.00
Medium (26 to 75 transplants/y) 1.26 (1.05-1.51) 0.012
Large (>75 transplants/y) 1.08 (0.90-1.29) 0.423
Transplant center size by bed number
Small (<250) 1.00
Medium (251-500) 0.92 (0.83-1.01) 0.081
Large (>500) 1.08 (0.98-1.20) 0.121
Teaching hospital 1.33 (1.03-1.72) 0.029
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